, 17-Department of Biostatistic and clinical research, CHU de Caen, F-14000 Caen, France 18-Department of clinical hematology, Makassed General Hospital

. Inserm-umr-1236,

. Inserm-umr-1232,

E. Hoster, M. Dreyling, and W. Klapper, A new prognostic index ( MIPI ) for patients with advanced-stage mantle cell lymphoma, Blood, vol.111, issue.2, pp.558-566, 2019.

M. Dreyling, G. Lenz, and E. Hoster, Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs porgession-free survival in mantle-cell lymphoma: results of prospective randomized trial of the European MCL network, Blood, vol.105, issue.7, pp.2677-2684, 2005.

R. Delarue, C. Haioun, and V. Ribrag, CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma : a phase 2 from the Groupe d'Etude des Lymphomes de l'Adulte, Blood, vol.121, issue.1, pp.48-53, 2013.

O. Hermine, E. Hoster, and J. Walewski, Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma ( MCL Younger ): a randomised , open-label , phase 3 trial of the European Mantle Cell Lymphoma Network, Lancet, vol.388, pp.565-575, 2016.

M. S. Czuczman, A. Goy, D. Lamonica, D. A. Graf, and M. C. Munteanu, Phase II study of bendamustine combined with rituximab in relapsed / refractory mantle cell lymphoma : efficacy , tolerability , and safety findings, Ann Hematol, vol.94, pp.2025-2032, 2015.

C. Visco, S. Finotto, and R. Zambello, Combination of Rituximab , Bendamustine , and Cytarabine for Patients With Mantle-Cell Non-Hodgkin Lymphoma Ineligible for Intensive Regimens or Autologous Transplantation, J Clin Oncol, vol.31, issue.11, pp.1442-1449, 2013.

R. Gaël, M. Lopez-guerra, and P. Milpied, Cancer Therapy : Preclinical Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms and Requires Oxidative Stress and Caspase-Independent Signaling, Clin Cancer Res, vol.14, issue.21, pp.6907-6916, 2008.

C. Visco, S. Castegnaro, and K. Chieregato, The cytotoxic effects of bendamustine in combination with cytarabine in mantle cell lymphoma cell lines, Blood Cells, Mol Dis, vol.48, pp.68-75, 2012.

G. Visani, L. Malerba, and P. M. Stefani, BeEAM ( bendamustine , etoposide , cytarabine , melphalan ) before autologous stem cell transplantation is safe and effective for resistant / relapsed lymphoma patients, Blood, vol.118, issue.12, pp.3419-3426, 2011.

G. Visani, P. M. Stefani, and S. Capria, Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce à 72% 3-years PFS in resistant lymphoma, Blood, vol.124, pp.3029-3032, 2014.

C. Touzeau, C. Leux, and R. Bouabdallah, Autologous stem cell transplantation in mantle cell lymphoma: A report from the SFGM-TC, Ann Hematol, vol.93, issue.2, pp.233-242, 2014.

B. D. Cheson, S. J. Horning, and B. Coiffier, Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, J Clin Oncol, vol.17, p.1244, 1999.

S. P. Chantepie, S. Garciaz, and E. Tchernonog, Bendamustine-based conditioning prior to autologous stem cell transplantation ( ASCT ): Results of a French multicenter study of 474 patients from LYmphoma Study Association ( LYSA ) centers, Am J Hematol, vol.93, pp.729-735, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01860419

L. Scrucca, A. Santucci, and F. Aversa, Competing risk analysis using R: an easy guide for clinicians, Bone Marrow Transplant, vol.40, issue.4, pp.381-387, 2007.

L. Scrucca, A. Santucci, and F. Aversa, Regression modeling of competing risk using R: an in depth guide for clinicians, Bone Marrow Transplant, vol.45, issue.9, pp.1388-1395, 2010.

L. Gouill, S. Thieblemont, C. Lucie, and O. , Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma, N Engl J Med, vol.377, pp.1250-1260, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02329536

M. L. Wang, R. Simon, and M. Peter, Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-cell Lymphoma, N Engl J Med, vol.369, issue.6, pp.507-516, 2013.

A. M. Redondo, D. Valc, A. P. Gonz, J. Gayoso, and I. Jarque, Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma : a phase 2 study from the GELTAMO group, Br J Haematol, vol.184, pp.797-807, 2019.

S. Gilli, U. Novak, and B. M. Taleghani, BeEAM conditioning with bendamustinereplacing BCNU before autologous transplantation is safe and effective i n lymphoma patients, Ann Hematol, vol.96, pp.421-429, 2017.

T. Noesslinger, M. Panny, and R. Simanek, High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients , without renal toxicity, Eur J Haematol, vol.101, issue.5, pp.326-331, 2018.

I. Prediletto, S. A. Farag, and U. Bacher, High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients, Bone Marrow Transplant, pp.41409-41428, 2019.

K. Saleh, A. Danu, and S. Koscielny, A retrospective , matched paired analysis comparing bendamustine containing BeEAM versus BEAM conditioning regimen : results from a single center experience, Leuk Lymphoma, vol.59, issue.11, pp.2580-2587, 2018.

J. Jo, B. W. Kang, and G. Jang, BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin ' s lymphoma patients : comparative analysis of efficacy and toxicity, Ann Hematol, vol.87, pp.43-48, 2008.

J. Olivieri, F. Mosna, and M. Pelosini, A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma : An Observational Study on 1038 Patients From Fondazione Italiana Linfomi, Journal: Am erican Journ al of Hem at ology, vol.24, issue.9, pp.1814-1822, 2018.

W. Type, Research Article Date Submitted by the Author, 2019.

, Clinical Hematology Garciaz, Sylvain; Paoli-Calmettes Institute

E. Durot, University Hospital Centre Reims, Clinical Hematology Houot

. Inserm-umr-1236,

B. Tessoulin, Clinical Hematology TOURNILHAC

. Hopital-rene-huguenin, Clinical Hematology Gyan

L. Fornecker and . Centre, Clinical Hematology Bouabdallah

, « Par délibération de son Conseil en date du 10 Novembre 1972, l'Université n'entend donner aucune approbation ni improbation aux opinions émises dans les thèses ou mémoires. Ces opinions doivent être considérées comme propres à leurs auteurs